Association of Increased LDL Cholesterol with Reduced Prostate Cancer Risk
Overview
In a large UK Biobank cohort, elevated low-density lipoprotein cholesterol (LDL) levels were associated with a decreased risk of developing prostate cancer (PCa). This inverse relationship persisted after adjusting for genetic, metabolic, and cardiovascular factors, challenging the conventional view that lower LDL is always beneficial.
Background
Prostate cancer is the second most common solid tumor in men worldwide. While metabolic syndrome components like obesity and dyslipidemia have been linked to PCa risk, the role of hepatic function and lipid metabolism remains unclear. Experimental data suggest PCa cells depend on cholesterol uptake, yet epidemiological studies paradoxically report higher PCa incidence at very low LDL levels. This study aimed to clarify the association between systemic LDL levels, hepatic biomarkers, and PCa risk using UK Biobank data.
Data Highlights
Variable
Hazard Ratio (HR)
95% Confidence Interval
p-value
LDL ≥ 3.65 mmol/L
0.83
0.77–0.90
<0.01
ALT ≥ 50 U/L
0.69
0.56–0.84
<0.01
Father with PCa
1.34
1.16–1.54
<0.01
Good health index
1.14
1.05–1.24
<0.01
Key Findings
Elevated LDL cholesterol (≥ 3.65 mmol/L) was significantly associated with a 17% reduced risk of prostate cancer (HR 0.83, p < 0.01).
Higher alanine aminotransferase (ALT ≥ 50 U/L) levels also showed a protective association against PCa (HR 0.69, p < 0.01).
A positive family history of prostate cancer (father affected) increased PCa risk by 34% (HR 1.34, p < 0.01).
A better self-rated health index was paradoxically associated with a modestly increased PCa risk (HR 1.14, p < 0.01).
Statistical models adjusted for age, ethnicity, BMI, diabetes, and cardiovascular comorbidities confirmed the robustness of these associations.
Despite statistically significant differences in hepatic biomarkers between PCa cases and controls, absolute differences were small.
Clinical Implications
These findings suggest that higher systemic LDL levels may confer a protective effect against prostate cancer development, contrasting with traditional cardiovascular risk paradigms. Clinicians should consider the complex role of lipid metabolism in PCa risk assessment and recognize that aggressive LDL lowering might have unintended oncological consequences. Further research is warranted to elucidate underlying mechanisms and guide lipid management in men at risk for prostate cancer.
Conclusion
The study reveals an inverse association between elevated LDL cholesterol and prostate cancer risk in a large population cohort, highlighting a lipid paradox that challenges existing assumptions. This underscores the need for nuanced interpretation of lipid profiles in prostate cancer risk stratification.
References
UK Biobank Study 2024 -- Association of Increased Low-Density Lipoprotein Cholesterol with Prostate Cancer Risk
Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.
